RHEUMATOID ARTHRITIS

Testing the anti-osteoclastic function of biologic DMARDs

A variety of biologic DMARDs now exist for the treatment of rheumatoid arthritis, but we don’t really know how these drugs function in vivo. Can time-lapse intravital imaging distinguish the modes of action of DMARDs by comparing response to joint destruction in mouse models of arthritis?

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Biologic DMARD mechanisms.

References

  1. 1.

    Shim, J. H., Stavre, Z. & Gravallese, E. M. Bone loss in rheumatoid arthritis: basic mechanisms and clinical implications. Calcif. Tissue Int. 102, 533–546 (2018).

  2. 2.

    Burmester, G. R. et al. Managing rheumatic and musculoskeletal diseases — past, present and future. Nat. Rev. Rheumatol. 13, 443–448 (2017).

  3. 3.

    Matsuura, Y. et al. In vivo visualisation of different modes of action of biological DMARDs inhibiting osteoclastic bone resorption. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2017-212880 (2018).

  4. 4.

    Dimitroulas, T. et al. Biologic therapies and systemic bone loss in rheumatoid arthritis. Autoimmun. Rev. 12, 958–966 (2013).

  5. 5.

    Robling, A. D. & Stout, S. D. Morphology of the drifting osteon. Cells Tissues Organs 164, 192–204 (1999).

  6. 6.

    Kliwinski, C. et al. Prophylactic administration of abatacept prevents disease and bone destruction in a rat model of collagen-induced arthritis. J. Autoimmun. 25, 165–171 (2005).

  7. 7.

    Kikuta, J. et al. Dynamic visualization of RANKL and Th17-mediated osteoclast function. J. Clin. Invest. 123, 866–873 (2013).

  8. 8.

    Axmann, R. et al. CTLA-4 directly inhibits osteoclast formation. Ann. Rheum. Dis. 67, 1603–1609 (2008).

  9. 9.

    Schett, G. Cells of the synovium in rheumatoid arthritis. Osteoclasts. Arthritis Res. Ther. 9, 203 (2007).

  10. 10.

    Cutolo, M. et al. CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production. Arthritis Res. Ther. 11, R176 (2009).

Download references

Acknowledgements

The authors thank S. Paolino, S. Soldano, R. Brizzolara and staff members at the Research Laboratory and Division of Clinical Rheumatology of the University of Genova for their support in the compilation of the manuscript.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Maurizio Cutolo.

Ethics declarations

Competing interests

M.C. declares he has received university research funds from Actelion Pharmaceuticals Ltd, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, and Horizon Pharma. A.S. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Cutolo, M., Sulli, A. Testing the anti-osteoclastic function of biologic DMARDs. Nat Rev Rheumatol 14, 446–448 (2018). https://doi.org/10.1038/s41584-018-0046-0

Download citation